Compare Abbott Laboratories (ABT) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs C.H. Robinson Worldwide, Inc. — how do they compare? Abbott Laboratories trades at $95.27 (market cap $166.94B), while C.H. Robinson Worldwide, Inc. trades at $189.82 (market cap $22.49B). The key difference: Abbott Laboratories is far larger — about 7.4× C.H. Robinson Worldwide, Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | CHRW | |
|---|---|---|
Market Cap | $166.94B | $22.49B |
Sector | Health | Industrials |
52-Week High | $136.62 | $200.59 |
52-Week Low | $82.57 | $96.82 |
Enterprise Value | $193.69B | $23.98B |
Dividend Yield | 2.63% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CH Robinson Worldwide (CHRW) trades at $190.95, up 0.58% with a bullish technical outlook. The stock shows strong profitability with ROE of 34.84% and has beaten earnings estimates for three consecutive quarters. Recent acquisitions like DeSpir Logistics and AI technology launches position the company for growth in logistics efficiency. Valuation metrics appear elevated with P/E of 38.18, though revenue has declined from 2022 peaks to $16.23B in 2025.
The outlook remains positive with analyst consensus target of $198.83 representing 4% upside. Key opportunities include AI-driven supply chain optimization and industry consolidation benefits, while risks involve freight market volatility and competitive pressures. Cash flow generation remains healthy with $915M operating cash flow in 2025 supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
